All articles tagged with #hepatocellular carcinoma
Liver cancer, often called a 'silent killer,' can develop with subtle early symptoms such as abdominal discomfort, occasional fever, changes in urine or stool, and persistent tiredness. Early detection through awareness of these signs and medical evaluation is crucial for improving treatment outcomes, especially in high-risk individuals.
Tempest Therapeutics (TPST) stock is up 325% as the clinical-stage oncology company prepares to release updated study results from a Phase 1b/2 combination study of TPST-1120 with atezolizumab and bevacizumab as a first-line treatment for hepatocellular carcinoma. Investors are eagerly awaiting the results, with heavy trading volume indicating high expectations. If the study fails to deliver positive news, TPST stock may lose the momentum it has gained.
Researchers at the University of Toronto and Insilico Medicine have developed a potential treatment for hepatocellular carcinoma (HCC) with an AI drug discovery platform called Pharma.AI. The creation of the potential drug was accomplished in just 30 days from the selection of the target and after synthesizing just seven compounds. The AI system was also able to predict cancer patient survival rates using doctors’ notes with an accuracy rate of over 80%.